Heart failure & cardiomyopathies
Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators
Authors' conclusion
Class 1C AADs effectively suppressed PVCs in patients with NICM and ICDs, leading to increases in LVEF and biventricular pacing percentage. In this limited sample, their use was safe.
Study context
- Population
- Patients with nonischemic cardiomyopathy and implantable cardioverter-defibrillators (ICDs) treated with flecainide or propafenone, Hospital of the University of Pennsylvania, 2014–202223 flecainide, 11 propafenone
- Participants
- 34 patients
- Exposure
- During vs before class 1C AAD treatment
- Outcome
- PVC burden, LVEF and biventricular pacing percentage before vs during class 1C AAD treatment
Methodological detailssingle-centre, before–after comparison, Most patients had failed other AADs (62%) or catheter ablation (68%) before class 1C AAD initiation
- Single-centre
- Before–after comparison
- Most patients had failed other AADs (62%) or catheter ablation (68%) before class 1C AAD initiation
Main finding
As reported in the abstract
PVC burden
- Left ventricular ejection fraction (LVEF) increased from 33% ± 9% to 37% ± 10%
- P = 0.01
- Biventricular pacing percentage increased from 85% ± 9% to 93% ± 7%
- P = 0.01
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators. JACC Clin Electrophysiol. Published 27 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →